Advisory board members gives valuable outside view in research and business
Prof. Dr. Thorsten Bach | Professor of Organic Chemistry, Technical University of Munich, Germany
Prof. Bach became full professor at the Technical University of Munich in 2000. He is specialized in catalysis, photochemistry and organometallic chemistry. A particular focus in his group lays on the total synthesis of bioactive natural products. Professor Bach authored nearly 200 publications and patents so far. Furthermore, his work was awarded by several renowned research prices, e.g. Leibniz-Preis, AstraZeneca Research Award, Novartis European Young Investigator Award, Degussa Award for Chirality in Chemistry 2006. Since 2006 he his elected Member of the German Academy of Sciences, Leopoldina (Halle, Saale).
Prof. K. Peter C. Vollhardt | Professor of Chemistry, University of California at Berkeley USA
Dr. Peter C. Vollhardt is Professor at the Department of Chemistry, University of California at Berkeley, Senior Principal Investigator at the Chemical Science Division, Lawrence Berkeley National Laboratory, and Assistant Dean to the College of Chemistry. As one of the world’s foremost organic chemists, he received many renowned, outstanding scientific awards.
Professor Vollhardt has more than 35 years of experience in the application of transition metals to enable the synthesis of complex natural and unnatural products. His outstanding scientific work led to over 265 scientific papers. In addition, he authored the standard college textbook on organic chemistry and serves as Chief Editor for the journal Synlett.
Hardy Debuch, PhD | Founder and Head of DHD Management Consulting AG, Germany
Hardy Debuch has more than 30 years of experience in the pharmaceutical industry. He assumed leading positions in research and marketing with E. Merck, Darmstadt/Germany and Röhm Pharma, Germany before he joined Schwarz Pharma, Germany in 1983 as a Board member, responsible to change Schwarz Pharma from a German-oriented company to a global market player. In 1995, Hardy Debuch founded his own consulting company DHD Management Consulting AG. Moreover, his clients are, beside German pharmaceutical companies, mainly Japanese and US companies.
Michael Bogenstaetter, PhD | Vice President, Strategy & Corporate Development MDS Inc., Toronto Canada
Michael Bogenstaetter has over 15 years experience in biopharmaceutical research and life science management & strategy. Since 2008, Michael is VP of Strategy & Corporate Development at MDS Inc, driving strategic acquisitions and divestitures. Before he advised leading multinational pharma & biopharma companies on key strategic and operational issues as a Project Leader and member of the Health Care practice of The Boston Consulting Group (Boston office). Prior, Michael was an Associate Director at Novartis Institutes for BioMedical Research (NIBR) in Cambridge, MA and medicinal chemist with Johnson & Johnson Pharmaceutical Research & Development in La Jolla, CA.
Michael Bogenstaetter accomplished the total synthesis of Adociasulfate 1 as a Feodor Lynen Scholar of the Alexander von Humboldt-Foundation with Professor Larry E. Overman at University of California Irvine. In addition, he earned his PhD in Organic Chemistry from Ludwig-Maximilians-University in Munich, Germany working with Professor Dr. Wolfgang Steglich and holds a full time MBA from London Business School.
Sina Afra | Co-Founder of Undo Labs, New York and Istanbul
Sina Afra has co-founded Undo Labs, a New York City and Istanbul-based design and innovation studio in 2014. Till 2014 Sina Afra was Managing Director and CEO at Markafoni as well as Chairman at brandsExclusive since April 2010. Before Sina was Managing Director at ebay Turkey preceding a position as Director of Corporate Development for eBay Germany and member of the German Leadership Team. Indeed, before joining eBay, Sina Afra has been with KPMG as principal (Frankfurt, Germany). Besides, he specialized in the areas of Value Based Management, Reporting, Planning and Cost Accounting and was leading the “Strategy, Process & Transformation” Team with 80 team members.